DBV Technologies has refreshed its at-the-market equity facility, restoring capacity to raise up to USD 150 million as the company prepares to submit a BLA for its VIASKIN Peanut Patch. The filing replenishes an ATM program originally established in 2025 after DBV drew approximately USD 65 million from the facility to support manufacturing, regulatory activities, and commercial preparation.
Proceeds are earmarked for manufacturing expansion, BLA-related activities across both of DBV's pediatric peanut-allergy indications, and launch preparation for the 4-7-year-old population, if approved. The company's most recent quarterly update disclosed cash and equivalents of USD 174.9 million as of June 30, 2026, providing runway into the third quarter of 2027, but R&D and SG&A expenses have risen sharply as the company builds US commercial infrastructure ahead of a potential launch.
VIASKIN Peanut Patch is an epicutaneous immunotherapy delivering peanut allergen through intact skin to desensitize allergic children. The Phase III VITESSE trial in children aged 4-7 met its primary endpoint in December 2025, with 46.6% of treated patients meeting responder criteria versus 14.8% on placebo. DBV had originally targeted a BLA filing in the first half of 2026 but pushed the timeline to the third quarter after extended, non-data-related discussions with the FDA over CMC and biostatistical data formatting. A separate BLA for toddlers aged 1-3, supported by the ongoing COMFORT Toddlers safety study, is expected in the second half of 2026.